031sek
4,0 %
Date:2024-05-21Time:14:05:50Latest report:Q4-2023List:First NorthTicker:BIOSGN
Market Cap:44 msekEnterprise Value:42 msekNet Sales:- msekEarnings:-27,0 msekEmployees:0ISIN:SE0016013460

Ratios

10-year key figure history for Biosergen turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Biosergen with index and moving average MA50 and MA200.

Stockprice:0,31
MA50:0,37
MA200:0,82
Price/MA200:-62,5 %
RSI (14):46,9
Price/MA50:-15,5 %

Description

Biosergen conducts biopharmaceutical research and development through its subsidiary Biosergen AS. Biosergen is a so-called No Research Development Only company, which organizationally and financially focuses all its resources on clinical development. The company is developing BSG005, a potentially degrading antifungal, which has shown significant safety and potency advantages over competing antifungals. The biosergen will initially use BSG005 against invasive fungal infections such as immunosuppressed AIDS cancer and transplant patients.

Biotechnology